The Tapestri® Single-cell MRD (scMRD) AML Multiomics Assay offers deep genotypic and immunophenotypic insights into MRD signatures within individual cells

Tapestri®单细胞MRD（scMRD）AML多组学分析为单个细胞内MRD特征提供了深入的基因型和免疫表型分析

Data recently published by Memorial Sloan Kettering Cancer Center demonstrate the assay's capability to identify single cells predictive of AML relapse

纪念斯隆-凯特琳癌症中心最近发表的数据证明了该分析方法能够识别预测AML复发的单细胞

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2023 /PRNewswire/ -- Mission Bio, a leader in single-cell multi-omic solutions for precision medicine, announced the commercial launch of the Tapestri® Single-cell MRD (scMRD) AML Multiomics Assay. The company designed the scMRD AML Multiomics Assay to bring unprecedented resolution to disease relapse and recurrence in acute myeloid leukemia (AML), demonstrating the potential of single-cell DNA and protein multiomics to identify therapeutic targets in recurrent AML..

2023年9月26日，加利福尼亚州南旧金山/PRNewswire/-精密医学单细胞多组学解决方案领导者Mission Bio宣布商业推出Tapestri®单细胞MRD（scMRD））AML多组学分析。该公司设计了scMRD AML多组学检测方法，为急性髓性白血病（AML）的疾病复发和复发带来前所未有的解决方案，证明了单细胞DNA和蛋白质多组学在复发性AML中鉴定治疗靶点的潜力。。

'Through our early access program, world-leading clinicians and scientists within academia and the biopharma industry have provided robust validation showing that our scMRD AML Multiomics Assay can provide impactful insights into AML evolution and patient relapse,' said Todd Druley, MD, PhD, Chief Medical Officer of Mission Bio.

Todd Druley博士说：“通过我们的早期获取计划，学术界和生物制药行业的世界领先临床医生和科学家提供了有力的验证，表明我们的scMRD AML多组学检测可以为AML进展和患者复发提供有影响的见解。”Mission Bio首席医疗官。

'By simultaneously interrogating DNA and protein targets at single-cell resolution and characterizing genotypic and immunophenotypic drifts over disease course, our assay not only identifies patients with recurrent AML, but potentially offers clinicians actionable treatment targets. Tapestri could transform care with comprehensive MRD detection for potentially guiding targeted treatments in AML, multiple myeloma (MM), and other blood cancers.'.

'通过同时以单细胞分辨率询问DNA和蛋白质靶标并表征疾病过程中的基因型和免疫表型漂移，我们的检测不仅可以识别复发性AML患者，还可能为临床医生提供可行的治疗靶点。Tapestri可以通过全面的MRD检测改变护理，以潜在地指导AML，多发性骨髓瘤（MM）和其他血液癌症的靶向治疗。

As the only solution to integrate genotypic and immunophenotypic assessment, the scMRD AML Multiomics Assay targets 40 genes for single-cell DNA sequencing based on current international AML MRD guidelines, such as European LeukemiaNet, and 17-plex antibody-oligonucleotide conjugate (AOC) panel curated for key biomarkers associated with AML MRD..

作为整合基因型和免疫表型评估的唯一解决方案，scMRD AML多组学检测根据目前的国际AML MRD指南（如欧洲白血病网）和17-plex抗体寡核苷酸偶联物（AOC）小组针对40个基因进行单细胞DNA测序为与AML MRD相关的关键生物标志物。。

Through a seamlessly integrated workflow, the assay allows clinician-researchers to:

通过无缝集成的工作流程，该测定法可使临床医生研究人员：

Distinguish true MRD from pre-leukemic or precursor clones with a limit of detection of 0.01%,

区分真正的MRD与白血病前期或前体克隆，检出限为0.01%，

Reveal clonal architecture (co-occurrence and zygosity of mutation) and uncover the order of acquisition of mutations (phylogeny),

揭示克隆结构（突变的共现和接合性）并揭示突变的获得顺序（系统发育），

Track clonal dynamics and immunophenotypic drifts through disease course to identify therapeutic targets and therapy-resistance subclones.

通过疾病过程追踪克隆动力学和免疫表型漂移以鉴定治疗靶标和治疗抗性亚克隆。

'Relapse continues to be a major challenge in cancer care, especially in the treatment of patients with AML. The problem is that current tools, like bulk NGS and flow cytometry, lack the clonal resolution and specificity to detect the treatment-resistant cancer cells still hiding in the shadows,' said P.J.M.

'复发仍然是癌症治疗中的主要挑战，特别是在AML患者的治疗中。问题在于，目前的工具，如大量NGS和流式细胞仪，缺乏克隆分辨率和特异性来检测仍然隐藏在阴影中的抗治疗癌细胞，“P.J.M。

(Peter) Valk, PhD, Principal Investigator at Erasmus MC in Rotterdam, Netherlands. 'Mission Bio's unique approach to characterizing MRD could dramatically change how we stratify patients in clinical trials and create personalized care strategies in the future.'.

（Peter）Valk博士，荷兰鹿特丹Erasmus MC首席研究员Mission Bio独特的MRD表征方法可以极大地改变我们如何在临床试验中对患者进行分层，并在未来创建个性化护理策略。

A recent study published in Science Advances and led by Wenbin Xiao, MD, PhD from the lab of world-leading leukemia specialist & physician-scientist Ross Levine, MD, Deputy Physician in Chief for Translational Research at MSK demonstrated the potential of the scMRD AML Multiomics Assay to better predict AML recurrence.

最近在Science Advances上发表的一项研究由MSK转化研究副主任医师，世界领先的白血病专家和医师科学家Ross Levine博士实验室的Wenbin Xiao博士领导，证明了scMRD的潜力AML多组学检测可以更好地预测AML复发。

The researchers found that the assay could detect clinically relevant variants missed by bulk next-generation sequencing with 0.01% limit of detection. Additionally, the researchers tapped the multiomic capabilities of the assay to illustrate the clonal architecture distinguishing leukemic clones from preleukemic clones and hematopoietic clones..

研究人员发现，该检测方法可以检测出大量下一代测序遗漏的临床相关变异，检测限为0.01%。此外，研究人员利用该检测方法的多组学功能来说明区分白血病克隆与白血病前克隆和造血克隆的克隆结构。。

Taken together, the data suggest that the scMRD AML Multiomics Assay could help identify AML relapse and has the potential to provide data-driven guidance to healthcare professionals regarding personalized treatment strategies, disease monitoring, and clinical trial stratification.

总之，数据表明，scMRD AML多组学检测可以帮助确定AML复发，并有可能为医疗保健专业人员提供有关个性化治疗策略，疾病监测和临床试验分层的数据驱动指导。

Mission Bio continues to provide its customers with innovative solutions for clonal profiling and surveillance, including single-cell multi-omic tools for studying other blood cancers such as MM. The new scMRD AML Multiomics Assay is now commercially available. For more information on the assay and the bioinformatics analysis and reporting capabilities, visit https://missionbio.com/applications/oncology/mrd-aml/..

Mission Bio继续为客户提供克隆分析和监测的创新解决方案，包括用于研究MM等其他血液癌症的单细胞多组学工具。新的scMRD AML多组学分析现已商业化。有关测定以及生物信息学分析和报告功能的更多信息，请访问https://missionbio.com/applications/oncology/mrd-aml/..

About Mission Bio

关于Mission Bio

Mission Bio is a leading life science company, specializing in the advancement of single-cell DNA and multi-omic analysis. The company's Tapestri Platform is unique in its capabilities, offering an unparalleled level of granularity and precision that is critical for complex research areas such as cancer studies, pharmaceutical development, and advanced cell and gene therapies.

Mission Bio是一家领先的生命科学公司，专门从事单细胞DNA和多组学分析的发展。该公司的Tapestri平台在其功能上独一无二，提供无与伦比的粒度和精确度，这对于癌症研究，药物开发以及先进的细胞和基因治疗等复杂研究领域至关重要。

Unlike traditional methods such as bulk sequencing, Tapestri provides a level of precision that opens the door for more tailored and effective treatment strategies. Researchers globally depend on Tapestri to identify rare cell populations, understand mechanisms of therapeutic resistance and response, and establish key quality metrics for next-generation medical treatments.

与传统方法（如批量测序）不同，Tapestri提供了一定程度的精确度，为更加量身定制和有效的治疗策略打开了大门。全球研究人员依靠Tapestri来识别稀有细胞群，了解治疗抵抗和反应的机制，并为下一代药物治疗建立关键的质量指标。

Founded in 2014, Mission Bio has secured investment from firms including Mayfield Fund, Novo Growth, Cota Capital, and Agilent Technologies. With the Tapestri Platform, Mission Bio is setting the standard in the field, contributing significantly to the progress of personalized medicine and targeted therapies.

Mission Bio成立于2014年，已获得包括Mayfield基金，Novo Growth，Cota Capital和Agilent Technologies在内的公司的投资。通过Tapestri平台，Mission Bio正在为该领域设定标准，为个性化医疗和靶向治疗的进展做出重大贡献。

To learn more about Mission Bio and the Tapestri Platform, please visit missionbio.com..

要了解有关Mission Bio和Tapestri平台的更多信息，请访问missionbio.com。。

Media ContactConsort Partners for Mission Bio[email protected]

媒体联系Mission Bio的合作伙伴[电子邮件保护]

SOURCE Mission Bio

资源Mission Bio